Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hunterase ICV approved in Japan for MPS II

Jan. 25, 2021

Galecto Biotech identifies new LGALS1 and/or LGALS3 inhibitors

Jan. 25, 2021

Oramed begins randomization in phase III study of oral insulin capsule ORMD-0801

Jan. 22, 2021

Lyndra initiates phase I study of its rosuvastatin extended-release capsule

Jan. 22, 2021

Cell therapy targeting BCL11A gene safely induces erythrocyte fetal hemoglobin

Jan. 22, 2021

U.S. IND application cleared for UX-701 gene therapy for Wilson disease

Jan. 22, 2021

FDA approves Darzalex Faspro for newly diagnosed light-chain amyloidosis

Jan. 18, 2021

Glutamine aids and abets senescent cell survival

Jan. 15, 2021

Bimagrumab improves traits in patients with type 2 diabetes and obesity

Jan. 15, 2021

Fochon Pharmaceuticals synthesizes new URAT1 inhibitors

Jan. 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...